- Home
- WFC vs AZN Comparison
WFC vs AZN Comparison
Compare WFC & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WFC | AZN |
|---|---|---|
| Founded | 1852 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.6B | 285.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WFC | AZN |
|---|---|---|
| Price | $74.26 | $190.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 1 |
| Target Price | ★ $97.37 | N/A |
| AVG Volume (30 Days) | ★ 14.6M | 1.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.39% | 1.66% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.46 | $10.13 |
| Revenue Next Year | $4.55 | $6.21 |
| P/E Ratio | ★ $14.15 | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $58.42 | $61.24 |
| 52 Week High | $97.76 | $212.71 |
Technical Indicators
Market Signals| Indicator | WFC | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 25.55 | 54.67 |
| Support Level | $71.95 | $89.28 |
| Resistance Level | $78.37 | $211.32 |
| Average True Range (ATR) | 2.43 | 3.22 |
| MACD | -0.85 | -5.15 |
| Stochastic Oscillator | 1.57 | 1.66 |
Price Performance
Historical ComparisonAbout WFC Wells Fargo & Company
Wells Fargo is one of the largest banks in the United States, with approximately $2.1 trillion in balance-sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the US market.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.